Biomarkers for ALK and ROS1 in Lung Cancer Immunohistochemistry and Fluorescent In Situ Hybridization

被引:21
作者
Luk, Peter P. [1 ]
Selinger, Christina I. [1 ]
Mahar, Annabelle [1 ]
Cooper, Wendy A. [1 ,2 ,3 ]
机构
[1] Royal Prince Alfred Hosp, Dept Tissue Pathol & Diagnost Oncol, Sydney, NSW, Australia
[2] Univ Sydney, Cent Clin Sch, Sydney, NSW, Australia
[3] Western Sydney Univ, Sch Med, Sydney, NSW, Australia
关键词
ANAPLASTIC LYMPHOMA KINASE; EML4-ALK FUSION GENE; COPY NUMBER; FISH; ADENOCARCINOMAS; REARRANGEMENT; CRIZOTINIB; IHC; IDENTIFICATION; RECEPTOR;
D O I
10.5858/arpa.2017-0502-RA
中图分类号
R446 [实验室诊断]; R-33 [实验医学、医学实验];
学科分类号
1001 ;
摘要
Context.-A small proportion of non-small cell lung cancers harbor rearrangements of ALK or ROS1 genes, and these tumors are sensitive to targeted tyrosine kinase inhibitors. It is crucial for pathologists to accurately identify tumors with these genetic alterations to enable patients to access optimal treatments and avoid unnecessary side effects of less effective agents. Although a number of different techniques can be used to identify ALK- and ROS1-rearranged lung cancers, immunohistochemistry and fluorescence in situ hybridization are the mainstays. Objective.-To review the role of immunohistochemistry in assessment of ALK and ROS1 rearrangements in lung cancer, focusing on practical issues in comparison with other modalities such as fluorescence in situ hybridization. Data Sources.-This manuscript reviews the current literature on ALK and ROS1 detection using immunohistochemistry and fluorescence in situ hybridization as well as current recommendations. Conclusions.-Although fluorescence in situ hybridization remains the gold standard for detecting ALK and ROS1 rearrangement in non-small cell lung cancer, immunohistochemistry plays an important role and can be an effective screening method for detection of these genetic alterations, or a diagnostic test in the setting of ALK.
引用
收藏
页码:922 / 928
页数:7
相关论文
共 54 条
[1]   Mouse Model for ROS1-Rearranged Lung Cancer [J].
Arai, Yasuhito ;
Totoki, Yasushi ;
Takahashi, Hiroyuki ;
Nakamura, Hiromi ;
Hama, Natsuko ;
Kohno, Takashi ;
Tsuta, Koji ;
Yoshida, Akihiko ;
Asamura, Hisao ;
Mutoh, Michihiro ;
Hosoda, Fumie ;
Tsuda, Hitoshi ;
Shibata, Tatsuhiro .
PLOS ONE, 2013, 8 (02)
[2]   ROS1 Rearrangements Define a Unique Molecular Class of Lung Cancers [J].
Bergethon, Kristin ;
Shaw, Alice T. ;
Ou, Sai-Hong Ignatius ;
Katayama, Ryohei ;
Lovly, Christine M. ;
McDonald, Nerina T. ;
Massion, Pierre P. ;
Siwak-Tapp, Christina ;
Gonzalez, Adriana ;
Fang, Rong ;
Mark, Eugene J. ;
Batten, Julie M. ;
Chen, Haiquan ;
Wilner, Keith D. ;
Kwak, Eunice L. ;
Clark, Jeffrey W. ;
Carbone, David P. ;
Ji, Hongbin ;
Engelman, Jeffrey A. ;
Mino-Kenudson, Mari ;
Pao, William ;
Iafrate, A. John .
JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (08) :863-870
[3]   Parallel FISH and Immunohistochemical Studies of ALK Status in 3244 Non-Small-Cell Lung Cancers Reveal Major Discordances [J].
Cabillic, Florian ;
Gros, Audrey ;
Dugay, Frederic ;
Begueret, Hugues ;
Mesturoux, Laura ;
Chiforeanu, Dan Cristian ;
Dufrenot, Leila ;
Jauffret, Vincent ;
Dachary, Dominique ;
Corre, Romain ;
Lespagnol, Alexandra ;
Soler, Gwendoline ;
Dagher, Julien ;
Catros, Veronique ;
Le Calve, Michele ;
Merlio, Jean-Philippe ;
Belaud-Rotureau, Marc-Antoine .
JOURNAL OF THORACIC ONCOLOGY, 2014, 9 (03) :295-306
[4]   Native and Rearranged ALK Copy Number and Rearranged Cell Count in Non-Small Cell Lung Cancer Implications for ALK Inhibitor Therapy [J].
Camidge, D. Ross ;
Skokan, Margaret ;
Kiatsimkul, Porntip ;
Helfrich, Barbara ;
Lu, Xian ;
Baron, Anna E. ;
Schulte, Nathan ;
Maxson, DeLee ;
Aisner, Dara L. ;
Franklin, Wilbur A. ;
Doebele, Robert C. ;
Varella-Garcia, Marileila .
CANCER, 2013, 119 (22) :3968-3975
[5]   Screening of ROS1 Rearrangements in Lung Adenocarcinoma by Immunohistochemistry and Comparison with ALK Rearrangements [J].
Cha, Yoon Jin ;
Lee, Jae Seok ;
Kim, Hye Ryun ;
Lim, Sun Min ;
Cho, Byoung Chul ;
Lee, Chang Young ;
Shim, Hyo Sup .
PLOS ONE, 2014, 9 (07)
[6]   The anaplastic lymphoma kinase in the pathogenesis of cancer [J].
Chiarle, Roberto ;
Voena, Claudia ;
Ambrogio, Chiara ;
Piva, Roberto ;
Inghirami, Giorgio .
NATURE REVIEWS CANCER, 2008, 8 (01) :11-23
[7]   Immunohistochemistry is a Reliable Screening Tool for Identification of ALK Rearrangement in Non-Small-Cell Lung Carcinoma and is Antibody Dependent [J].
Conklin, Chris M. J. ;
Craddock, Kenneth J. ;
Have, Cherry ;
Laskin, Janessa ;
Couture, Christian ;
Ionescu, Diana N. .
JOURNAL OF THORACIC ONCOLOGY, 2013, 8 (01) :45-51
[8]   Molecular biology of lung cancer [J].
Cooper, Wendy A. ;
Lam, David C. L. ;
O'Toole, Sandra A. ;
Minna, John D. .
JOURNAL OF THORACIC DISEASE, 2013, 5 :S479-S490
[9]   Canadian Anaplastic Lymphoma Kinase Study A Model for Multicenter Standardization and Optimization of ALK Testing in Lung Cancer [J].
Cutz, Jean-Claude ;
Craddock, Kenneth J. ;
Torlakovic, Emina ;
Brandao, Guilherme ;
Carter, Ronald F. ;
Bigras, Gilbert ;
Deschenes, Jean ;
Izevbaye, Iyare ;
Xu, Zhaolin ;
Greer, Wenda ;
Yatabe, Yasushi ;
Ionescu, Diana ;
Karsan, Aly ;
Jung, Sungmi ;
Fraser, Richard S. ;
Blumenkrantz, Miriam ;
Lavoie, Josee ;
Fortin, Flechere ;
Bojarski, Anna ;
Cote, Gilbert B. ;
van den Berghe, Janette A. ;
Rashid-Kolvear, Fariborz ;
Trotter, Martin ;
Sekhon, Harmanjatinder S. ;
Albadine, Roula ;
Danh Tran-Thanh ;
Gorska, Isabelle ;
Knoll, Joan H. M. ;
Xu, Jie ;
Blencowe, Ben ;
Iafrate, A. John ;
Hwang, David M. ;
Pintilie, Melania ;
Gaspo, Rania ;
Couture, Christian ;
Tsao, Ming-Sound .
JOURNAL OF THORACIC ONCOLOGY, 2014, 9 (09) :1255-1263
[10]   Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib [J].
Eberhard, DA ;
Johnson, BE ;
Amler, LC ;
Goddard, AD ;
Heldens, SL ;
Herbst, RS ;
Ince, WL ;
Jänne, PA ;
Januario, T ;
Johnson, DH ;
Klein, P ;
Miller, VA ;
Ostland, MA ;
Ramies, DA ;
Sebisanovic, D ;
Stinson, JA ;
Zhang, YR ;
Seshagiri, S ;
Hillan, KJ .
JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (25) :5900-5909